Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3945262 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LY3945262 Part A (SAD) | EXPERIMENTAL | Single Ascending Doses (SAD) of LY3945262 administered orally |
| Placebo Part A (SAD) | PLACEBO_COMPARATOR | Placebo administered orally |
| LY3945262 Part B (MAD) | EXPERIMENTAL | Multiple Ascending Doses (MAD) of LY3945262 administered orally. Participants will also receive 2 doses of Midazolam (one before and one with LY3945262) administered orally. |
| Placebo Part B (MAD) | PLACEBO_COMPARATOR | Placebo administered orally. Participants will also receive 2 doses of Midazolam (one before and one with placebo) administered orally. |
| LY3945262 Part C (Test) | EXPERIMENTAL | LY3945262 tablet formulation administered orally |
| LY3945262 Part C (Reference) | ACTIVE_COMPARATOR | LY3945262 capsule formulation administered orally |
| Name | Type | Description |
|---|---|---|
| LY3945262 | DRUG | Administered Orally |
| Placebo | DRUG | Administered Orally |
| Midazolam | DRUG | Administered orally |
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and electrocardiogram (ECG). * To qualify as Japanese for the purpose of this study, the participant must be first generation Japanese, de...